Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket studyLingfang Xia, Xiaohua Wu, Jin Peng et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 39
Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical CancerXingtao Long, Qi Zhou, Dong Wang et al.|Clinical Medicine Insights Oncology|2023Cited by 11